
Pharmacally
Heart Failure
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Heart Failure
Health TidingsAZD5462 Shows Early Effects in Phase IIb Heart Failure TrialThe LUMINARA Phase IIb trial found early cardiac and vascular effects with AZD5462, an investigational oral relaxin agonist, in patients with chronic heart failure.Fact-Checked
Clinical TrialsCould a Once-Daily Polypill Improve Heart Failure Outcomes? POLY-HF Trial Shows Better Cardiac Function, Adherence, and Fewer HospitalizationsA once-daily polypill combining three guideline-directed heart failure therapies improved cardiac function, treatment adherence, and reduced heart failure hospitalizations compared with enhanced usual care in the Phase 3…Fact-Checked
Clinical TrialsBridgeBio Presents New ATTRibute-CM Data Supporting Acoramidis at Heart Failure 2026New ATTRibute-CM analyses presented at Heart Failure 2026 showed that acoramidis delivered sustained benefits across heart failure progression, cardiovascular outcomes, biomarkers, and patient-reported quality of life in ATTR-CM.Fact-Checked
Health TidingsEU Expands Kerendia Label: Bayer’s Finerenone Approved for Broader Heart Failure PopulationThe EU expands Kerendia’s label to heart failure with LVEF ≥40%, with Phase III data supporting significant reductions in cardiovascular death and heart failure events.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.